CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	December 2023 Warrant Exchange	Public Offering	Nonrelated Party	Related Party	Common Stock	Common Stock Public Offering	Common Stock Nonrelated Party	Common Stock Related Party	Additional Paid-In Capital	Additional Paid-In Capital December 2023 Warrant Exchange	Additional Paid-In Capital Public Offering	Additional Paid-In Capital Nonrelated Party	Additional Paid-In Capital Related Party	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Series 9 Preferred Stock at Redemption Value	Series 9 Preferred Stock at Redemption Value Series 9 Preferred Stock at Redemption Value	Series 9 Preferred Stock at Redemption Value Common Stock	Series 9 Preferred Stock at Redemption Value Additional Paid-In Capital
Balance, beginning (in shares) at Dec. 31, 2022																		0
Balance, beginning (in shares) at Dec. 31, 2022						3,181,578
Balance, beginning at Dec. 31, 2022	$ (14,982)					$ 3				$ 17,908					$ 0	$ (32,893)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation	141									141
Issuance of warrants with convertible note	39									39
Net loss	(1,565)															(1,565)
Balance, ending (in shares) at Mar. 31, 2023																		0
Balance, ending at Mar. 31, 2023	(16,367)					$ 3				18,088					0	(34,458)		$ 0
Balance, ending (in shares) at Mar. 31, 2023						3,181,578
Balance, beginning (in shares) at Dec. 31, 2022																		0
Balance, beginning (in shares) at Dec. 31, 2022						3,181,578
Balance, beginning at Dec. 31, 2022	(14,982)					$ 3				17,908					0	(32,893)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Change in fair value of convertible note receivable	0
Net loss	(6,194)
Balance, ending (in shares) at Jun. 30, 2023																		0
Balance, ending at Jun. 30, 2023	(11,844)					$ 3				27,240					0	(39,087)		$ 0
Balance, ending (in shares) at Jun. 30, 2023						3,194,431
Balance, beginning (in shares) at Mar. 31, 2023																		0
Balance, beginning (in shares) at Mar. 31, 2023						3,181,578
Balance, beginning at Mar. 31, 2023	$ (16,367)					$ 3				18,088					0	(34,458)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock issued during period, shares, new issues (in shares)	12,853
Stock issued during period, value, new issues	$ 180									180
Stock based compensation	2,461									2,461
Issuance of warrants with convertible note	928									928
JV obligation reclassified to equity	5,583
Change in fair value of convertible note receivable	0
Net loss	(4,629)															(4,629)
Balance, ending (in shares) at Jun. 30, 2023																		0
Balance, ending at Jun. 30, 2023	$ (11,844)					$ 3				27,240					0	(39,087)		$ 0
Balance, ending (in shares) at Jun. 30, 2023						3,194,431
Balance, beginning (in shares) at Dec. 31, 2023	0																0	0
Balance, beginning (in shares) at Dec. 31, 2023	3,197,771					3,197,771
Balance, beginning at Dec. 31, 2023	$ (31,629)					$ 3				26,327					0	(57,959)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for conversion of convertible securities (in shares)								2,621,516	266,272
Stock issued during period, value, conversion of convertible securities				$ 8,691	$ 923			$ 3					$ 8,688	$ 923
Inducement loss on debt conversions	6,732									6,732
Common stock issued to Xeriant, Inc. (in shares)						298,395
Common stock issued for exercise of warrants (in shares)						389,287
Common shares issued for cashless exercise of warrants	0					$ 1				(1)
Common shares issued for cashless exercise of options (in shares)						92,728
Common and preferred shares issued via merger (in shares)						2,075,743												11,302
Common and preferred shares issued via merger	25,605					$ 2				14,301								$ 11,302
Capital contribution - forgiveness of related party payable	380									380
Stock based compensation (in shares)						977,699
Stock based compensation	5,792					$ 1				5,791
Cumulative translation adjustment	(166)														(166)
Series 9 preferred stock dividend accrued	(61)									(61)
Net loss	(2,602)															(2,602)
Balance, ending (in shares) at Mar. 31, 2024																		11,302
Balance, ending at Mar. 31, 2024	$ 13,665					$ 10				63,080					(166)	(60,561)		$ 11,302
Balance, ending (in shares) at Mar. 31, 2024						9,919,411
Balance, beginning (in shares) at Dec. 31, 2023	0																0	0
Balance, beginning (in shares) at Dec. 31, 2023	3,197,771					3,197,771
Balance, beginning at Dec. 31, 2023	$ (31,629)					$ 3				26,327					0	(57,959)		$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued for cashless exercise of options (in shares)	92,728
Change in fair value of convertible note receivable	$ 59
Net loss	(17,312)
Balance, ending (in shares) at Jun. 30, 2024																	7,752	7,752
Balance, ending at Jun. 30, 2024	$ 10,575					$ 27				78,206					(139)	(75,271)		$ 7,752
Balance, ending (in shares) at Jun. 30, 2024	26,841,686					26,841,686
Balance, beginning (in shares) at Mar. 31, 2024																		11,302
Balance, beginning (in shares) at Mar. 31, 2024						9,919,411
Balance, beginning at Mar. 31, 2024	$ 13,665					$ 10				63,080					(166)	(60,561)		$ 11,302
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for conversion of convertible securities (in shares)																		(3,550)	2,999,187
Stock issued during period, value, conversion of convertible securities																	$ 177	$ (3,550)	$ 3	$ 3,724
Deemed dividend related to Series 9 preferred stock exchange																	$ (177)			$ (177)
Stock based compensation	(59)									(59)
Cumulative translation adjustment	(32)														(32)
Common shares issued in exchange of warrants (in shares)						1,492,415
Common shares issued in exchange of warrants	1,981					$ 2				1,979
Deemed dividend related to December 2023 warrant exchange		$ (283)									$ (283)
Common shares issued in exchange of warrants (in shares)						20,528
Common shares issued for exercise of warrants	2									2
Stock issued during period, shares, new issues (in shares)							9,300,203
Stock issued during period, value, new issues			$ 8,675				$ 9					$ 8,666
Common shares issued as settlement of accrued compensation (in shares)						2,680,459
Common shares issued as settlement of accrued compensation	1,192					$ 3				1,189
Common shares issued as prepayment for marketing services (in shares)						429,483
Common shares issued as prepayment for services	335									335
Series 9 preferred stock dividend accrued	(250)									(250)
Change in fair value of convertible note receivable	59														59
Net loss	(14,710)															(14,710)
Balance, ending (in shares) at Jun. 30, 2024																	7,752	7,752
Balance, ending at Jun. 30, 2024	$ 10,575					$ 27				$ 78,206					$ (139)	$ (75,271)		$ 7,752
Balance, ending (in shares) at Jun. 30, 2024	26,841,686					26,841,686